EAErdem Ak

Erdem Ak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Erdem Ak has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessment of protective effect of the losartan against cisplatin-induced nephrotoxicity in mice

    by Selçuk Teke, Gülsen Bayrak, Erdem Ak, Ali Can Korkmaz, Şakir Necat Yilmaz, Ali Delibaş

    Cisplatin is widely used in pediatric oncology but is limited by its dose-dependent nephrotoxicity. The renin–angiotensin–aldosterone system (RAAS) has been implicated in cisplatin-induced renal injury. Losartan, an angiotensin II receptor blocker, may offer renal protection; however, its effects on apoptosis and regeneration in this context remain unclear. This study aimed to investigate the potential protective role of losartan against cisplatin-induced nephrotoxicity, specifically by assessing its impact on apoptosis and tubular regeneration. Fifteen female BALB/c mice were randomly assigned to three groups ( n = 5 per group): Control, cisplatin (12.7 mg/kg, i.p., single dose), and cisplatin + losartan (10 mg/kg/day, oral). Losartan was administered for nine consecutive days, starting 4 days before cisplatin exposure. Histopathological examination, active caspase-3 immunostaining (for apoptosis), and 5-bromo-2-deoxyuridine (BrdU) labeling (for cell proliferation) were performed. Glomerular and tubular injury scores, caspase-3 H-scores, and BrdU-positive cell counts were statistically analyzed using the Kruskal–Wallis H and Mann–Whitney U tests. Cisplatin significantly increased glomerular ( p = 0.006, p = 0.005, p = 0.006) and tubular injury scores ( p = 0.008, p = 0.007, p = 0.007, p = 0.007, p = 0.007), elevated active caspase-3 expression ( p = 0.002), and reduced BrdU-positive cell counts ( p = 0.009) compared to control. Losartan co-treatment significantly reduced glomerular ( p = 0.008, p = 0.005, p = 0.008) and tubular injury ( p = 0.008, p = 0.008, p = 0.009, p = 0.008, v) and decreased caspase-3 expression ( p = 0.009). Additionally, BrdU-positive cell counts were significantly higher in the cisplatin + losartan group compared to both control and cisplatin groups ( p = 0.009), indicating enhanced regeneration. Losartan mitigates cisplatin-induced nephrotoxicity by suppressing apoptosis and promoting tubular regeneration. These findings support the potential therapeutic role of RAAS inhibition in preventing cisplatin-associated renal injury.


  • Open Access

    Prevalence and Related Factors of Euthyroid Sick Syndrome in Children with Untreated Cancer According to Two Different Criteria

    by Ali Duyu, Elvan Çağlar Çıtak, Erdem Ak, Serhan Kupeli, Begül Yağcı Küpeli, İbRahim Bayram, Gülay Sezgin, Gülçin Eskendari, Kerem Sezer

    Objective: In this study, we evaluated the frequency of euthyroid sick syndrome (ESS) among patients with childhood cancer and its association with the stage of disease, nutritional parameters and cytokines levels. Methods: Eighty newly diagnosed children were included in the study. ESS was assessed in two different ways. According to criteria 1 ESS was present if free triiodothyronine (fT3) was below the lower limit and free thyroxine was within the normal or low limits, thyroid-stimulating hormone (TSH) was in the normal range. According to criteria 2, in addition to the above, it was required that reverse triiodothyronine (rT3) be performed and was higher than normal limits. Results: Three of our pediatric patients had subclinical hypothyroidism and two had subclinical hyperthyroidism. Out of 75 patients, ESS was identified in 14 (17.3%) according to criteria 1 and in eight (10.6%) according to criteria 2. Only fT3 levels were significantly different in the ESS (+) and ESS (-) groups (p < 0.05) according to criteria 1. A significantly negative correlation between interleukin (IL)6 and fT3 was found, according to both sets of criteria. tumor necrosis factor alpha was negatively correlated with fT3 levels only in the criteria 1 group. There were no correlations between IL-1 beta and fT3, free thyroxine, rT3 and TSH levels. Conclusion: ESS may occur in childhood cancer and thyroid function testing should be performed routinely when cancer is diagnosed.